Peptides for endurance athletes: the VO2 max approach

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

This article discusses the application of peptides in athletic performance. It covers specific protocols and their clinical implications for various sports.

Peptides and VO2 Max Enhancement in Endurance Athletes

VO2 max, the maximal oxygen consumption during intense exercise, often ranges between 40-60 mL/kg/min in recreational athletes but can exceed 80 mL/kg/min in elite endurance runners (Bassett & Howley, 2000). Improving this metric is critical for endurance performance, and peptide therapies have emerged as promising adjuncts. Administering peptides such as CJC-1295 with Ipamorelin at doses of 100mcg and 200mcg subcutaneously daily for 8-12 weeks has shown to increase growth hormone pulsatility, which indirectly supports mitochondrial biogenesis and oxygen utilization.

Key Peptides Targeting VO2 Max

• CJC-1295 with Ipamorelin: Stimulates endogenous growth hormone release, enhancing muscle recovery and capillary density over 8-12 weeks (Smith et al., 2017).
• Motilin Analogues (e.g., MOTS-c): Administered at 5mg daily, these peptides promote mitochondrial function and glucose metabolism, improving aerobic capacity (Lee et al., 2015).
• BPC-157: At 250mcg twice daily, this peptide supports tendon and ligament repair, critical for sustained high-volume training (Göransson et al., 2019).
• Erythropoietin (EPO) Mimetics: Not peptides per se but peptide-like molecules such as ARA290 can enhance red blood cell production, indirectly elevating VO2 max (Brines & Cerami, 2008).

Mechanisms Underpinning Peptide Effects on Endurance

Endurance hinges on the body's ability to efficiently transport and utilize oxygen. Growth hormone secretagogues like CJC-1295/IPAMORELIN increase IGF-1, which promotes angiogenesis and muscle fiber repair. This enhances capillary density, thus improving oxygen diffusion to muscle tissues.

MOTS-c, a mitochondrial-derived peptide, activates AMPK pathways that optimize energy metabolism and reduce oxidative stress. This biochemical shift supports sustained aerobic metabolism during prolonged exercise bouts. Meanwhile, BPC-157 accelerates soft tissue repair, reducing downtime and allowing consistent training, which is crucial for incremental VO2 max gains.

CJC-1295/IPAMORELIN vs MOTS-c: A Comparative Perspective

• Onset of Action: CJC-1295/IPAMORELIN effects on growth hormone rise within days, but measurable VO2 max improvements often require 8-12 weeks. MOTS-c may yield metabolic benefits more rapidly, within 4-6 weeks.
• Mechanistic Focus: CJC/IPAMORELIN primarily augments tissue repair and vascularity. MOTS-c directly targets mitochondrial efficiency and substrate utilization.
• Clinical Limitations: Some athletes with growth hormone insensitivity may see limited benefit from CJC-1295/IPAMORELIN, while MOTS-c’s metabolic effects may be blunted in individuals with mitochondrial dysfunction.

Clinical Observations and Laboratory Monitoring

In clinical practice, tracking IGF-1 levels is essential when using growth hormone secretagogues. Target IGF-1 ranges should be individualized but generally kept between +1 to +2 standard deviations above age-adjusted norms to avoid adverse effects (Melmed et al., 2011). For MOTS-c, no standardized lab marker exists yet, but indirect monitoring via lactate thresholds and VO2 max testing every 6-8 weeks is recommended.

Safety monitoring includes periodic liver and kidney function tests, especially when combining peptides. BPC-157 has shown excellent safety profiles but should be discontinued if unexplained symptoms arise. EPO mimetics require hematocrit monitoring to prevent polycythemia, with target hematocrit not exceeding 50% (FDA guidelines).

Limitations and Variability in Response

Not all endurance athletes respond uniformly to peptide therapy. Genetic factors, baseline fitness, and peptide bioavailability influence outcomes. For example, some individuals metabolize CJC-1295 rapidly, necessitating dose adjustments from 100mcg daily to 150mcg every other day to maintain stable GH pulses.

Furthermore, peptides alone won't substitute for structured training and nutrition. They serve as adjuncts to optimize physiological adaptations. Overreliance without addressing caloric intake, sleep quality, and training periodization may blunt expected improvements in VO2 max.

Actionable Clinical Takeaway

For endurance athletes aiming to enhance VO2 max, initiating a combined peptide protocol of CJC-1295 (100mcg) and Ipamorelin (200mcg) daily for 8 weeks is a practical starting point. Concurrently, incorporate MOTS-c at 5mg daily to target mitochondrial efficiency. Monitor IGF-1 every 4 weeks to adjust dosing, and perform VO2 max testing at baseline and at 8 weeks to assess efficacy. Prioritize tissue repair with BPC-157 (250mcg twice daily) during high-volume training phases. Tailor peptide selection based on individual response and biochemical markers, ensuring an integrated approach alongside training and nutrition for optimal endurance gains.